6 completed, 3 recruiting, 2 unknown, 1 terminated. 12 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 6, Recruiting 3, Unknown 2, Terminated 1 |
| Phase 2 | 4 | Recruiting 2, Completed 1, Unknown 1 |
Follow Olfaction Disorders: new trials by email Literature Review of Olfaction Disorders trials Research Report on Olfaction Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical Versus Injection PRP for Olfactory Dysfunction Intranasal Injection of Autologous PRP, Carrier-Assisted Topical Application of Autologous PRP, platelet-rich plasma - Olfactory Dysfunction, Anosmia | Phase 3 | Recruiting | Taipei Veterans General Hospital, Taiwan | 60 | 2025-09-11 | 2026-10-05 |
| Stellate Ganglion Block With Lidocaine for the Treatment of COVID-19-Induced Parosmia Stellate Ganglion Block, Placebo - Parosmia | Phase 3 | Unknown | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 44 | 2024-02-15 | 2024-10-23 |
| Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID) Trigeminal Nerve Stimulation (TNS), Active Smell Training (ST), Placebo Smell Training (PBO) - Smell Dysfunction, Olfactory Disorder | Phase 2 / Phase 3 | Recruiting | Medical University of South Carolina | 145 | 2023-10-02 | 2026-04-02 |
| Effect of Hydralazine on Alzheimer's Disease Hydralazine hydrochloride 25mg tablets, Placebo - Alzheimer Disease | Phase 3 | Completed | Shahid Sadoughi University of Medical Sciences and Health Services | 228 | 2021-08-02 | 2026-09-09 |
| Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia intranasal spray ivermectin - Anosmia | Phase 2 / Phase 3 | Unknown | South Valley University | 117 | 2021-04-20 | 2022-04-22 |
| Effectiveness and Safety of Platelet Rich Plasma (PRP) on Persistent Olfactory Dysfunction Related to COVID-19 Platelet rich plasma (PRP), olfactory training - Anosmia, COVID-19 | Phase 2 / Phase 3 | Completed | Centre Hospitalier Universitaire Saint Pierre | 56 | 2021-02-01 | 2022-02-25 |
| Intranasal Insulin for COVID-19-related Smell Loss Insulin - Anosmia, Smell Loss | Phase 3 | Completed | Universidad Panamericana | 27 | 2021-01-04 | 2022-07-18 |
| GnRH Therapy on Cognition in Down Syndrome GnRH, gonadorelin acetate, 0.9% NaCl - Down Syndrome, Cognitive Decline | Phase 2 / Phase 3 | Recruiting | Nelly Pitteloud | 56 | 2020-08-27 | 2024-02-12 |
| Corticosteroid Nasal Spray in COVID-19 Anosmia mometasone furoate nasal spray - Covid19, Anosmia | Phase 3 | Completed | Benha University | 100 | 2020-08-08 | 2020-11-13 |
| Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia Cerebrolysin - Covid19 Related Anosmia and Aguesia | Phase 3 | Completed | Assiut University | 250 | 2020-08-01 | 2023-01-03 |
| Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity Budesonide Nasal, Physiological serum - Budesonide, Olfaction Disorders | Phase 3 | Completed | Fondation Ophtalmologique Adolphe de Rothschild | 120 | 2020-05-18 | 2026-01-06 |
| NAC for Head Trauma-induced Anosmia N Acetyl Cysteine, Placebo oral capsule - Anosmia, Head Trauma | Phase 3 | Terminated | University of Miami | 7 | 2018-10-12 | 2021-02-04 |
Anosmia (11) · COVID-19 (5) · Alzheimer Disease (2) · Post-Acute COVID-19 Syndrome (2) · Ageusia (1) · Cognitive Dysfunction (1) · Craniocerebral Trauma (1) · Down Syndrome (1)
Nervous System Diseases (12) · Neurologic Manifestations (12) · Pathological Conditions, Signs and Symptoms (12) · Sensation Disorders (12) · Signs and Symptoms (12) · Coronaviridae Infections (6) · Coronavirus Infections (6) · Infections (6) · Lung Diseases (6) · Nidovirales Infections (6) · Pneumonia (6) · Pneumonia, Viral (6) · RNA Virus Infections (6) · Respiratory Tract Diseases (6)
Olfactory Training (3) · Acetylcysteine (1) · Autonomic Nerve Block (1) · Control Groups (1) · Gonadotropin-Releasing Hormone (1) · Hydralazine (1) · Insulin (1) · Saline Solution (1) · Transcutaneous Electric Nerve Stimulation (1) · cerebrolysin (1)
Assiut University (1) · Benha University (1) · Centre Hospitalier Universitaire Saint Pierre (1) · Fondation Ophtalmologique Adolphe de Rothschild (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Medical University of South Carolina (1) · Nelly Pitteloud (1) · Shahid Sadoughi University of Medical Sciences and Health Services (1) · South Valley University (1) · Taipei Veterans General Hospital, Taiwan (1) · Universidad Panamericana (1) · University of Miami (1)
Egypt (3) · United States (2) · Belgium (1) · Canada (1) · France (1) · Iran (1) · Mexico (1) · Switzerland (1) · Taiwan (1)
Abdelhakim F Ghallab, MD (1) · Abdelrahman A Abdelalim, MD (1) · Ayman A Mohamady, MD (1) · Mihaela Horoi, PhD (1) · Mona A Elawady, MD (1) · Nelly Pitteloud, MD (1) · Rasha A Elsayed, MD (1) · Roy Casiano, MD (1) · Sherifa A Hamed, M.D. (1)
PMID 15023839, PMID 23875929, PMID 29557250, PMID 32253535, PMID 32690074, PMID 33320115, PMID 33429174, PMID 33453291, PMID 33862126, PMID 34792577, PMID 34830550, PMID 34870334, PMID 35065619, PMID 35320821, PMID 35389456, PMID 35904632, PMID 36048943, PMID 36063364, PMID 36164334, PMID 37652094, PMID 37950370
R01DC021179 (1)